Skip to main content
Premium Trial:

Request an Annual Quote

Fluidigm Expects 8 Percent Drop in Q1 Revenues, Withdraws 2020 Guidance

NEW YORK – Fluidigm said after the close of the market on Tuesday that it expects Q1 revenues of approximately $27.6 million.

Expected revenues would represent an 8 percent year-over-year decline from $30.1 million a year ago and fall short of analysts' average expectation of $29.3 million.

Fluidigm said that preliminary Q1 revenues include about $3 million in license revenue. The South San Francisco, California-based omics research tools firm said that it saw "significant slowdown" in customer activity beginning in China and spreading to all regions as Q1 and the COVID-19 pandemic progressed.

Widespread adoption of work-from-home or shelter-in-place policies caused many of the company's customers to reduce or suspend their activities, which adversely affected Q1 revenue, Fluidigm said, noting that results were not impacted by supply or manufacturing constraints.

Fluidigm also said that it is withdrawing its previously stated 2020 guidance due to the unknown duration and extent of the COVID-19 pandemic and how it will affect global operations.

As of March 31, 2020, Fluidigm had cash, cash equivalents, short-term investments, and restricted cash totaling about $49.6 million, compared to $60.7 million at the end of 2019. Cash flow in the quarter included a $5.2 million cash expenditure for the acquisition of InstruNor, announced in February, and $3.5 million of incoming cash from a licensing and legal settlement.

Fluidigm expects to release its full financial and operating results for Q1 and provide additional information on the impact of the COVID-19 pandemic in early May.

In mid-morning Wednesday trading on the Nasdaq, shares of Fluidigm were down about 8 percent at $1.93.

The Scan

Enzyme Involved in Lipid Metabolism Linked to Mutational Signatures

In Nature Genetics, a Wellcome Sanger Institute-led team found that APOBEC1 may contribute to the development of the SBS2 and SBS13 mutational signatures in the small intestine.

Family Genetic Risk Score Linked to Diagnostic Trajectory in Psychiatric Disorders

Researchers in JAMA Psychiatry find ties between high or low family genetic risk scores and diagnostic stability or change in four major psychiatric disorders over time.

Study Questions Existence of Fetal Microbiome

A study appearing in Nature this week suggests that the reported fetal microbiome might be the result of sample contamination.

Fruit Fly Study Explores Gut Microbiome Effects on Circadian Rhythm

With gut microbiome and gene expression experiments, researchers in PNAS see signs that the microbiome contributes to circadian rhythm synchronicity and stability in fruit flies.